Skip to main content
Erschienen in:

27.02.2024 | Research

Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study

verfasst von: Takuya Mikoshiba, Mariko Sekimizu, Takeyuki Kono, Ryoto Nagai, Taiji Kawasaki, Yoichiro Sato, Fumihiro Ito, Nana Nakahara, Seiji Shigetomi, Hiroyuki Ozawa

Erschienen in: Endocrine | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Lenvatinib achieves favorable therapeutic outcomes for patients with radioactive iodine therapy refractory differentiated thyroid cancer (DTC); however, its use is associated with a high incidence of adverse events. To avoid severe adverse events, planned drug holidays (PDH) have been proposed. This study aimed to evaluate treatment effects, identify prognostic factors, and investigate the usefulness of PDH in patients with unresectable DTC who received lenvatinib across the multi-institutions.

Methods

Fifty-one patients with unresectable DTC treated with lenvatinib were evaluated retrospectively. Overall survival (OS) and progression-free survival (PFS) were calculated, and prognostic factors were assessed. OS, PFS, and time to treatment failure (TTF) were compared between patients with and without PDH. Lenvatinib administration schedule was evaluated in PDH.

Results

The 3-year OS and PFS rate were 53.5% and 42.1%, respectively. Multivariate analysis revealed that presence of maximum size of lung metastasis ≥10 mm was independent prognostic factor for poorer OS and PFS, and histology other than papillary thyroid carcinoma was the independent prognostic factor for poorer PFS. Twenty-five patients (49%) treated with PDH. There were significant differences in OS, PFS, and TTF between patients with and without PDH. Various schedules were used in PDH. Eight (32%) patients required switch to the different administration schedule.

Conclusion

Our results suggest that PDHs may extend OS, PFS, and TTF. In patients with PDH, various schedules used for lenvatinib administration highlight the difficulty in determining a uniform administration schedule. Therefore, it is crucial to consider the optimal lenvatinib administration schedule on a case-by-case basis.

Literatur
  1. R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics. 2022. CA Cancer J. Clin. 72, 7–33 (2022)View ArticlePubMed
  2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Thyroid Carcinoma, Version 3, (2022). https://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​thyroid.​pdf. Accessed 1 November 2022
  3. M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 272, 621–630 (2015)View Article
  4. M.H. Taylor, S. Takahashi, J. Capdevila, M. Tahara, S. Leboulleux, N. Kiyota, C.E. Dutcus, R. Xie, B. Robinson, S. Sherman, M.A. Habra, R. Elisei, L.J. Wirth, Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 31, 1226–1234 (2021)View ArticlePubMedPubMed Central
  5. N. Kiyota, M. Tahara, B. Robinson, M. Schlumberger, S.I. Sherman, S. Leboulleux, E.K. Lee, T. Suzuki, M. Ren, K. Fushimi, L.J. Wirth, Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer 128, 2281–2287 (2022)View ArticlePubMed
  6. C. Masaki, K. Sugino, N. Saito, J. Akaishi, K.Y. Hames, C. Tomoda, A. Suzuki, K. Matsuzu, K. Ohkuwa, W. Kitagawa, M. Nagahama, K. Ito, Predictors of maximum efficacy of lenvatinib for real-world patients with differentiated thyroid carcinoma. Surg. Today 52, 1660–1669 (2022)View ArticlePubMed
  7. C. Suzuki, N. Kiyota, Y. Imamura, H. Goto, H. Suto, N. Chayahara, M. Toyoda, Y. Ito, A. Miya, A. Miyauchi, N. Otsuki, K.I. Nibu, H. Minami, Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. Head. Neck 41, 3023–3032 (2019)View ArticlePubMed
  8. H. Yamazaki, H. Iwasaki, K. Masudo, S. Toda, A. Matsui, Y. Rino, Prognostic significance of lung metastasis-related findings in lenvatinib treatment for differentiated thyroid cancer. Endocrine 78, 543–551 (2022)View ArticlePubMed
  9. M.M. Sabra, E.J. Sherman, R.M. Tuttle, Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. Cancer 123, 2955–2964 (2017)View ArticlePubMed
  10. H. Zhao, C.H. Liu, Y. Cao, L.Y. Zhang, Y. Zhao, Y.W. Liu, H.F. Liu, Y.S. Lin, X.Y. Li, Survival prognostic factors for differentiated thyroid cancer patients with pulmonary metastases: A systematic review and meta-analysis. Front. Oncol. 12, 990154 (2022). https://​doi.​org/​10.​3389/​fonc.​2022.​990154. eCollection 2022View ArticlePubMedPubMed Central
  11. N. Fukuda, K. Toda, X. Wang, A. Ohmoto, N. Hayashi, T. Urasaki, Y. Sato, K. Nakano, M. Ono, J. Tomomatsu, H. Mitani, S. Takahashi, Prognostic significance of 8 weeks’ relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients. Endocr J 68, 639–647 (2021)View ArticlePubMed
  12. M. Tahara, M.S. Brose, L.J. Wirth, T. Suzuki, H. Miyagishi, K. Fujino, C.E. Dutcus, A. Gianoukakis, Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 106, 61–68 (2019)View ArticlePubMed
  13. M. Tahara, Management of recurrent or metastatic thyroid cancer. ESMO Open 3(Suppl 1), e000359 (2018)View ArticlePubMedPubMed Central
  14. H. Iwamoto, H. Suzuki, S. Shimose, T. Niizeki, M. Nakano, T. Shirono, S. Okamura, Y. Noda, N. Kamachi, T. Nakamura, A. Masuda, T. Sakaue, T. Tanaka, D. Nakano, M. Sakai, T. Yamaguchi, R. Kuromatsu, H. Koga, T. Torimura, Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers 12, 1010 (2020)View ArticlePubMedPubMed Central
  15. C. Matsuyama, T. Enokida, Y. Ueda, S. Suzuki, T. Fujisawa, K. Ito, S. Okano, M. Tahara, Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front. Oncol. 13, 1139659 (2023). https://​doi.​org/​10.​3389/​fonc.​2023.​1139659View ArticlePubMedPubMed Central
  16. M. Tahara, H. Takami, Y. Ito, T. Okamoto, I. Sugitani, K. Sugino, S. Takahashi, H. Takeyama, H. Tsutsui, H. Hara, A. Mitsuma, Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer. J. Clin. Oncol. 39(Suppl 15), 6070 (2021)View Article
  17. Kuma Hospital. Doubling Time, Doubling Rate & Progression Calculator. https://​www.​kuma-h.​or.​jp/​english/​about/​doubling-time-progression-calculator/​ Released on 28 January 2019. Accessed 5 July 2023
  18. M. Schlumberger, M. Brose, R. Elisei, S. Leboulleux, M. Luster, F. Pitoia, F. Pacini, Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2, 356–358 (2014)View ArticlePubMed
  19. R.I. Haddad, M. Schlumberger, L.J. Wirth, E.J. Sherman, M.H. Shah, B. Robinson, C.E. Dutcus, A. Teng, A.G. Gianoukakis, S.I. Sherman, Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 56, 121–128 (2017)View ArticlePubMedPubMed Central
Metadaten
Titel
Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study
verfasst von
Takuya Mikoshiba
Mariko Sekimizu
Takeyuki Kono
Ryoto Nagai
Taiji Kawasaki
Yoichiro Sato
Fumihiro Ito
Nana Nakahara
Seiji Shigetomi
Hiroyuki Ozawa
Publikationsdatum
27.02.2024
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03744-0

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Antibiotika bei Bakteriämie – 7 versus 14 Tage

  • 21.01.2025
  • Sepsis
  • Nachrichten

Eine Bakteriämie lässt sich mit einer einwöchigen Antibiotikatherapie zumeist gut in den Griff bekommen: Die Sterberate ist nicht höher als unter zweiwöchiger Behandlung, zeigt eine Vergleichsstudie mit hospitalisierten Erkrankten. Allerdings muss die Therapie bei fast jedem Vierten verlängert werden.

"Die Erektionsstörung ist keine isolierte Erkrankung"

Werden Erektionsstörungen gut behandelt (und das ist möglich), steigt die Lebensqualität enorm. Tipps für eine gute Kommunikation mit den Patienten gibt Androloge Dr. med. Jann-Frederik Cremers in dieser Folge. Welche Fragen sollten gestellt und an welche Ursachen gedacht werden? Und was ist zu tun, wenn PDE-5-Hemmer und Lebensstilveränderungen nicht ausreichend wirken?

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.